IVA.PA Stock - Inventiva S.A.
Unlock GoAI Insights for IVA.PA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $14.72M | $17.48M | $12.18M | $4.19M | $372,000 |
| Gross Profit | $9.20M | $17.50M | $11.18M | $3.18M | $-474,000 |
| Gross Margin | 62.5% | 100.1% | 91.8% | 75.8% | -127.4% |
| Operating Income | $-97,558,000 | $-102,709,000 | $-57,110,000 | $-52,114,000 | $-29,718,000 |
| Net Income | $-184,212,000 | $-110,426,000 | $-54,274,000 | $-49,636,000 | $-33,619,000 |
| Net Margin | -1251.1% | -631.8% | -445.6% | -1183.5% | -9037.4% |
| EPS | $-3.08 | $-2.43 | $-1.31 | $-1.27 | $-0.99 |
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
Visit WebsiteEarnings History & Surprises
IVA.PAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 24, 2026 | — | — | — | — |
Q3 2025 | Sep 29, 2025 | $-0.54 | $-1.62 | -202.1% | ✗ MISS |
Q2 2025 | Apr 16, 2025 | $-0.45 | $-2.00 | -344.6% | ✗ MISS |
Q3 2024 | Sep 26, 2024 | $-1.22 | $-0.94 | +22.7% | ✓ BEAT |
Q2 2024 | May 22, 2024 | $-0.78 | $-1.13 | -46.3% | ✗ MISS |
Q3 2023 | Sep 28, 2023 | $-0.73 | $-1.31 | -80.1% | ✗ MISS |
Q1 2023 | Mar 30, 2023 | $-0.55 | $-0.59 | -7.3% | ✗ MISS |
Q4 2022 | Nov 11, 2022 | $-0.86 | $-0.72 | +16.2% | ✓ BEAT |
Q2 2022 | May 17, 2022 | $-0.79 | $-0.67 | +15.7% | ✓ BEAT |
Q4 2021 | Nov 11, 2021 | $-0.77 | $-0.37 | +52.0% | ✓ BEAT |
Q2 2021 | May 13, 2021 | $-0.27 | $-0.47 | -73.6% | ✗ MISS |
Q4 2020 | Nov 13, 2020 | $-0.32 | $-0.23 | +28.4% | ✓ BEAT |
Q2 2020 | May 14, 2020 | — | $-0.36 | — | — |
Q4 2019 | Nov 13, 2019 | — | $-0.93 | — | — |
Q2 2019 | May 15, 2019 | — | $-0.76 | — | — |
Q4 2018 | Nov 13, 2018 | — | $-0.86 | — | — |
Q2 2018 | May 15, 2018 | — | $-0.57 | — | — |
Q4 2017 | Nov 7, 2017 | — | $-0.67 | — | — |
Q1 2017 | Mar 27, 2017 | — | $-0.30 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-0.41 | — | — |
Latest News
Frequently Asked Questions about IVA.PA
What is IVA.PA's current stock price?
What is the analyst price target for IVA.PA?
What sector is Inventiva S.A. in?
What is IVA.PA's market cap?
Does IVA.PA pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to IVA.PA for comparison